No Data
No Data
New Study Demonstrates That SL-NAD+ Delivers NAD+ Into Cells
IX Biopharma's New Wafer Revolutionizes NAD+ Supplementation
IX Biopharma Widens Net Loss by 12% in FY2024
IX Biopharma's Net Attributable Loss Widens in Fiscal H2
IX Biopharma Full Year 2024 Earnings: S$0.014 Loss per Share (Vs S$0.013 Loss in FY 2023)
Financial Statements and Related Announcement-Full Yearly Results
No Data
No Data
hh488 : They trying to release some positive news prior to the payment of the rights. So don't get caught & jump in right away!